Auf dieser Seite
BOLT Bolt Biotherapeutics, Inc. - Common Stock
NASDAQ · Biotechnology · Auf SEC EDGAR ansehen ↗ Schließen Okt 2, 2026 10-K/10-Q Aug 11, 2026
$3,45
· % der 52-Wochen-Spanne
· über Tiefststand
· zu hoch
$3,1052-Wochen-Tief
$7,0152-Wochen-Hoch
Marktkapitalisierung (MRQ)
$7M
P/E (TTM)
-0.2
EPS (TTM)
$-21.98
Umsatz (TTM)
$5M
Ihre Abzeichen
52W-Spanne
$3–$7
Analystenbewertung
BUY
Kursziel
$29
P/E
-0.2
ROE
-111.6%
Nettogewinnmarge
-611.5%
Ihre Abzeichenleiste ist leer – heften Sie eine Kennzahl auf dieser Seite an.
BOLT Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$3.45
Marktkapitalisierung (MRQ)
$7M
P/E (TTM)
-0.2
EPS (TTM)
$-21.98
Umsatz (TTM)
$5M
ROE (TTM)
-111.6%
52W-Spanne
$3–$7
BOLT Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Spanne
Balken
Die Balkengranularität passt sich der ausgewählten Periode an – bewegen Sie den Mauszeiger über das Diagramm, um Eröffnungs-/Höchst-/Tiefst-/Schlusskurse für einen Balken anzuzeigen.
Aktiensplits
| Ex-Datum | Split | Typ |
|---|---|---|
| 9. Juni 2025 | 1-for-20 | Umgekehrt |
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
Umsatz$8M2020-12-31 → 2025-12-31
EPS$-17.852021-12-31 → 2025-12-31
Freier Cashflow$-40M2021-12-31 → 2025-12-31
Nettogewinnmarge-611.5%2021-12-31 → 2025-12-31
Bewertung & Kennzahlen
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
| Kennzahl | 5-Jahres-Trend | BOLT | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| P/E (TTM) | -0.25-Jahres-Durchschnitt ≈-11.4 | ≈-11.4 | · | · | |
| P/S (TTM) | 1.45-Jahres-Durchschnitt ≈648.7 | ≈648.7 | 1.8 | Fairer Wert | |
| K/B (MRQ) | 0.55-Jahres-Durchschnitt ≈7.1 | ≈7.1 | 1.0 | Unterbewertet | |
| Price / FCF (Kurs / FCF) | -0.25-Jahres-Durchschnitt ≈-18.7 | ≈-18.7 | · | · | |
| Price / Cash Flow (Kurs / Cashflow) | -0.25-Jahres-Durchschnitt ≈-19.3 | ≈-19.3 | · | · | |
| Price / Tangible Book (Kurs / Materieller Buchwert) | 0.25-Jahres-Durchschnitt ≈7.1 | ≈7.1 | · | · |
Der Median der Vergleichsgruppe wird pro Kennzahl standardisiert berechnet und stimmt möglicherweise nicht immer mit der für diese Aktie angezeigten TTM/MRQ-Basis überein.
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
| Kennzahl | 5-Jahres-Trend | BOLT | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Betriebsgewinnmarge (TTM) | -654.5%5-Jahres-Durchschnitt ≈-2265.5% | ≈-2265.5% | -51300.8% | Schwach | |
| EBITDA-Marge (TTM) | -635.0%5-Jahres-Durchschnitt ≈-2228.0% | ≈-2228.0% | -51300.8% | Schwach | |
| Pretax Margin (Vorgewinnmarge) | -433.7% | · | · | · | |
| Nettogewinnmarge (TTM) | -611.5%5-Jahres-Durchschnitt ≈-2299.1% | ≈-2299.1% | -50068.8% | Schwach | |
| ROA (TTM) | -49.6%5-Jahres-Durchschnitt ≈-43.1% | ≈-43.1% | -96.7% | Spitzenklasse | |
| ROE (TTM) | -111.6%5-Jahres-Durchschnitt ≈-68.8% | ≈-68.8% | -138.9% | Spitzenklasse | |
| ROIC | -136.2% | · | · | · |
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
| Kennzahl | 5-Jahres-Trend | BOLT | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Liquiditätsgrad (MRQ) | 2.65-Jahres-Durchschnitt ≈5.7 | ≈5.7 | 2.5 | Im Einklang | |
| Quick Ratio | 3.35-Jahres-Durchschnitt ≈5.5 | ≈5.5 | 3.0 | Unterdurchschnittlich |
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
| Kennzahl | 5-Jahres-Trend | BOLT | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Revenue YoY (Umsatz YoY) | 0.07%5-Jahres-Durchschnitt ≈167.1% | ≈167.1% | · | · | |
| Revenue CAGR 3Y (Umsatz CAGR 3J) | 10.3%5-Jahres-Durchschnitt ≈105.8% | ≈105.8% | · | · | |
| Revenue CAGR 5Y (Umsatz CAGR 5J) | 101.6% | · | · | · |
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
| Kennzahl | 5-Jahres-Trend | BOLT | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Asset Turnover (Umsatz / Vermögenswerte) | 0.15-Jahres-Durchschnitt ≈0.0 | ≈0.0 | 0.2 | Schwach | |
| Revenue / Employee (Umsatz / Mitarbeiter) | ≈$334.6K | · | · | · |
Wert · ≈ 5-Jahres-Durchschnitt · Branchenmedian · Urteil relativ zum Median
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
Durchschn. Überraschung
7.2%
Nächster Bericht
Nov 10, 2026
| Zeitraum | Bericht | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|---|
| 30. Juni 2026 | Aug 12, 2026 | $-4.57 | $-3.45 | -32.3% |
| 31. März 2026 | Mai 11, 2026 | $-4.31 | $-2.91 | -48.3% |
| 31. Dezember 2025 | $-3.84 | $-6.23 | 38.4% | |
| 30. September 2025 | $-3.72 | $-5.90 | 37.0% | |
| 30. Juni 2025 | $-4.46 | $-6.58 | 32.2% | |
| 31. März 2025 | $-5.80 | $-7.39 | 21.6% | |
| 31. Dezember 2024 | $-7.60 | $-7.75 | 2.0% |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $8M | $8M | $8M | $6M | $1M | $231.0K | |
| R&D Expense | $29M | $57M | $62M | $73M | $76M | $40M | |
| SG&A Expense | $14M | $18M | $23M | $23M | $18M | $9M | |
| Operating Expenses | $44M | $81M | $84M | $96M | $94M | $49M | |
| Operating Income | $-36M | $-73M | $-76M | $-90M | $-93M | $-49M | |
| Other Non-op | $3M | $10M | $7M | $2M | $-6M | $-12M | |
| Pretax Income | $-33M | $-63M | · | · | · | · | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-33M | $-63M | $-69M | $-88M | $-99M | $-61M | |
| EPS (Basic) | $-17.85 | $-33.06 | $-1.83 | $-2.36 | $-2.97 | · | |
| EPS (Diluted) | $-17.85 | $-33.06 | $-1.83 | $-2.36 | $-2.97 | · | |
| Shares (Basic) | 1,869,924 | 1,909,225 | 37,811,984 | 37,358,425 | 33,196,712 | 1,989,208 | |
| Shares (Diluted) | 1,869,924 | 1,909,225 | 37,811,984 | 37,358,425 | 33,196,712 | · | |
| EBITDA | $-35M | $-71M | $-74M | $-89M | $-92M | · |
Bilanz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $12M | $7M | $11M | $9M | $27M | $6M | |
| Short-term Investments | $16M | $40M | $91M | $160M | $159M | $17M | |
| Prepaid Expense | $3M | $3M | $4M | $4M | $3M | $3M | |
| Current Assets | $30M | $51M | $106M | $173M | $189M | $25M | |
| PP&E (Net) | $1M | $3M | $5M | $6M | $6M | $4M | |
| PP&E (Gross) | $9M | $10M | $11M | $10M | $8M | $5M | |
| Accum. Depreciation | $7M | $7M | $6M | $4M | $2M | $1M | |
| Other Non-current Assets | $138.0K | $62.0K | $2M | $1M | $1M | $909.0K | |
| Total Assets | $57M | $100M | $160M | $228M | $308M | $47M | |
| Accounts Payable | $1M | $2M | $3M | $4M | $4M | $2M | |
| Current Liabilities | $8M | $16M | $20M | $23M | $21M | $11M | |
| Capital Leases | $20M | $23M | $17M | $20M | $22M | $9M | |
| Other Non-current Liabilities | $132.0K | $0 | $43.0K | $42.0K | $210.0K | $329.0K | |
| Total Liabilities | $30M | $42M | $47M | $56M | $58M | $46M | |
| Common Stock | $0 | $0 | $0 | $0 | $0 | · | |
| Retained Earnings | $-461M | $-427M | $-364M | $-295M | $-207M | $-108M | |
| AOCI | $-21.0K | $97.0K | $37.0K | $-919.0K | $-321.0K | · | |
| Stockholders' Equity | $27M | $57M | $113M | $172M | $250M | $-105M | |
| Liabilities + Equity | $57M | $100M | $160M | $228M | $308M | $47M | |
| Shares Outstanding | 1,920,566 | 1,916,943 | 38,114,606 | 37,797,902 | 37,399,694 | 2,130,139 |
Cashflow
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| D&A | $1M | $2M | $2M | $2M | $1M | $611.0K | |
| Stock-based Comp | $3M | $7M | $9M | $10M | $8M | $1M | |
| Restructuring | $1M | $3M | $0 | · | · | · | |
| Other Non-cash | $-11M | $-7M | $-11M | $352.0K | $32M | · | |
| Operating Cash Flow | $-40M | $-61M | $-70M | $-77M | $-57M | $-47M | |
| CapEx | $72.0K | $41.0K | $206.0K | $2M | $2M | $3M | |
| Investing Cash Flow | $44M | $58M | $71M | $58M | $-232M | $-21M | |
| Stock Issued | $19.0K | $108.0K | $253.0K | $503.0K | $1M | $294.0K | |
| Net Stock Activity | $19.0K | $108.0K | $253.0K | $503.0K | $1M | · | |
| Financing Cash Flow | $19.0K | $108.0K | $253.0K | $503.0K | $311M | $40M | |
| Net Change in Cash | $4M | $-4M | $2M | $-18M | $22M | $-28M | |
| Free Cash Flow | $-40M | $-61M | $-70M | $-78M | $-59M | · |
Rentabilität
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Operating Margin | -469.3% | -949.9% | -967.5% | -1576.6% | -7364.1% | · | |
| Net Margin | -433.7% | -820.8% | -878.6% | -1537.8% | -7824.7% | · | |
| Pretax Margin | -433.7% | · | · | · | · | · | |
| EBITDA Margin | -452.5% | -926.8% | -943.9% | -1547.5% | -7269.4% | · | |
| ROA | -42.7% | -48.7% | -35.7% | -32.9% | -55.7% | · | |
| ROE | -102.2% | -97.7% | -57.4% | -48.9% | -37.6% | · | |
| ROIC | -136.2% | · | · | · | · | · |
Liquidität & Solvenz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 3.6 | 3.2 | 5.2 | 7.5 | 8.9 | · | |
| Quick Ratio | 3.3 | 3.0 | 5.0 | 7.3 | 8.7 | · |
Effizienz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | · |
Pro Aktie
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Book Value / Share | $13.80 | $1.49 | $2.96 | $4.54 | $6.69 | · | |
| Revenue / Share | $4.12 | $0.20 | $0.21 | $0.15 | · | · | |
| Cash Flow / Share | $-21.31 | $-1.61 | $-1.84 | $-2.05 | · | · | |
| Cash / Share | $6.09 | $0.19 | $0.28 | $0.24 | $0.73 | · | |
| EPS (TTM) | $-17.85 | $-33.06 | $-1.83 | $-2.36 | $-2.97 | · |
Wachstumsraten
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue YoY | 0.07% | -2.4% | 37.5% | 354.7% | 445.5% | · | |
| Revenue CAGR 3Y | 10.3% | 82.8% | 224.3% | · | · | · | |
| Revenue CAGR 5Y | 101.6% | · | · | · | · | · |
Bewertung (TTM)
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue TTM | $8M | $8M | $8M | $6M | $1M | $231.0K | |
| Net Income TTM | $-33M | $-63M | $-69M | $-88M | $-99M | $-61M | |
| Market Cap | $11M | $410M | $854M | $983M | $3.67B | · | |
| P/E | -0.3 | -0.3 | -12.2 | -11.0 | -33.0 | · | |
| P/S | 1.4 | 53.3 | 108.4 | 171.5 | 2908.9 | · | |
| P/B | 0.4 | 7.2 | 7.6 | 5.7 | 14.7 | · | |
| P / Tangible Book | 0.4 | 7.2 | 7.6 | 5.7 | 14.7 | · | |
| P / Cash Flow | -0.3 | -6.7 | -12.3 | -12.8 | -64.2 | · | |
| P / FCF | -0.3 | -6.7 | -12.2 | -12.5 | -61.7 | · | |
| Earnings Yield | -326.4% | -309.0% | -8.2% | -9.1% | -3.0% | · |
Gewinn- und Verlustrechnung
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.0K | $26.0K | $2M | $2M | $2M | $1M | $0 | $1M | $1M | $5M | $2M | $3M | $1M | $2M | $1M | $2M | |
| R&D Expense | $5M | $5M | $5M | $7M | $7M | $10M | $12M | $14M | $15M | $17M | $16M | $15M | $16M | $15M | $17M | $19M | |
| SG&A Expense | $2M | $3M | $3M | $3M | $4M | $4M | $4M | $4M | $5M | $6M | $6M | $6M | $6M | $6M | $6M | $5M | |
| Operating Expenses | $8M | $8M | $10M | $10M | $11M | $13M | $17M | $18M | $24M | $22M | $22M | $21M | $21M | $20M | $22M | $24M | |
| Operating Income | $-8M | $-8M | $-7M | $-8M | $-9M | $-12M | $-17M | $-16M | $-23M | $-17M | $-20M | $-18M | $-20M | $-18M | $-21M | $-22M | |
| Other Non-op | $654.0K | $357.0K | $454.0K | $559.0K | $649.0K | $1M | $980.0K | $1M | $1M | $6M | $2M | $2M | $2M | $1M | $1M | $587.0K | |
| Net Income | $-8M | $-7M | $-7M | $-7M | $-9M | $-11M | $-16M | $-15M | $-21M | $-11M | $-18M | $-16M | $-18M | $-17M | $-20M | $-22M | |
| EPS (Basic) | $-4.57 | $-4.31 | $-9.38 | $-3.72 | $-4.46 | $-5.76 | $-13.73 | $-7.93 | $-11.12 | $-0.28 | $-0.47 | $-0.43 | $-0.48 | $-0.45 | $-0.53 | $-0.58 | |
| EPS (Diluted) | $-4.57 | $-4.31 | $-9.38 | $-3.72 | $-4.46 | $-5.76 | $-13.73 | $-7.93 | $-11.12 | $-0.28 | $-0.47 | $-0.43 | $-0.48 | $-0.45 | $-0.53 | $-0.58 | |
| Shares (Basic) | 1,690,529 | 1,680,445 | · | 1,919,441 | 1,917,629 | 1,916,943 | · | 1,912,554 | 1,906,496 | 38,068,424 | · | 37,868,480 | 37,750,393 | 37,684,023 | · | 37,454,340 | |
| Shares (Diluted) | 1,690,529 | 1,680,445 | · | 1,919,441 | 1,917,629 | 1,916,943 | · | 1,912,554 | 1,906,496 | 38,068,424 | · | 37,868,480 | 37,750,393 | 37,684,023 | · | 37,454,340 | |
| EBITDA | $-8M | $-7M | · | $-8M | $-9M | $-12M | · | $-16M | $-23M | $-17M | · | $-18M | $-20M | $-18M | · | · |
Bilanz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $13M | $12M | $12M | $18M | $10M | $8M | $7M | $9M | $6M | $4M | $11M | $9M | $13M | $15M | $9M | $11M | |
| Short-term Investments | $5M | $11M | $16M | $14M | $25M | $30M | $40M | $44M | $67M | $87M | $91M | $111M | $112M | $112M | $160M | $161M | |
| Prepaid Expense | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $4M | $4M | $6M | $5M | $5M | $4M | $4M | |
| Current Assets | $21M | $26M | $30M | $36M | $38M | $43M | $51M | $57M | $77M | $95M | $106M | $125M | $131M | $132M | $173M | $175M | |
| PP&E (Net) | $571.0K | $1M | $1M | $2M | $2M | $2M | $3M | $4M | $4M | $4M | $5M | $5M | $6M | $6M | $6M | $7M | |
| PP&E (Gross) | $4M | $9M | $9M | $9M | $9M | $9M | $10M | $10M | $11M | $11M | $11M | $11M | $10M | $10M | $10M | $10M | |
| Accum. Depreciation | $4M | $8M | $7M | $7M | $7M | $6M | $7M | $7M | $7M | $6M | $6M | $5M | $5M | $4M | $4M | $3M | |
| Other Non-current Assets | $87.0K | $112.0K | $138.0K | $179.0K | $222.0K | $51.0K | $62.0K | $287.0K | $308.0K | $2M | $2M | $1M | $1M | $1M | $1M | $1M | |
| Total Assets | $40M | $48M | $57M | $65M | $75M | $86M | $100M | $109M | $124M | $143M | $160M | $175M | $191M | $206M | $228M | $246M | |
| Accounts Payable | $868.0K | $2M | $1M | $2M | $2M | $2M | $2M | $1M | $3M | $2M | $3M | $4M | $3M | $2M | $4M | $4M | |
| Current Liabilities | $8M | $7M | $8M | $10M | $12M | $14M | $16M | $18M | $18M | $17M | $20M | $19M | $18M | $16M | $23M | $24M | |
| Capital Leases | $19M | $19M | $20M | $21M | $22M | $22M | $23M | $15M | $16M | $17M | $17M | $18M | $19M | $20M | $20M | $21M | |
| Other Non-current Liabilities | $132.0K | $158.0K | $132.0K | $133.0K | $133.0K | $132.0K | $0 | $0 | $0 | $0 | $43.0K | $43.0K | $43.0K | $43.0K | $42.0K | $200.0K | |
| Total Liabilities | $28M | $28M | $30M | $33M | $37M | $39M | $42M | $37M | $38M | $39M | $47M | $47M | $49M | $48M | $56M | $57M | |
| Common Stock | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $1.0K | $1.0K | $1.0K | $0 | $1.0K | $1.0K | $0 | $0 | $0 | |
| Retained Earnings | $-476M | $-468M | $-461M | $-454M | $-447M | $-438M | $-427M | $-411M | $-396M | $-375M | $-364M | $-346M | $-330M | $-312M | $-295M | $-275M | |
| AOCI | $-44.0K | $-11.0K | $-21.0K | $-10.0K | $-6.0K | $40.0K | $97.0K | $205.0K | $-44.0K | $-36.0K | $37.0K | $-174.0K | $-229.0K | $-235.0K | $-919.0K | $-2M | |
| Stockholders' Equity | $13M | $20M | $27M | $32M | $39M | $47M | $57M | $72M | $86M | $104M | $113M | $128M | $142M | $158M | $172M | $188M | |
| Liabilities + Equity | $40M | $48M | $57M | $65M | $75M | $86M | $100M | $109M | $124M | $143M | $160M | $175M | $191M | $206M | $228M | $246M | |
| Shares Outstanding | 1,926,345 | 1,921,567 | 1,920,566 | 1,919,441 | 1,919,441 | 38,339,697 | 1,916,943 | 38,273,002 | 38,264,843 | 38,127,740 | 38,114,606 | 37,965,870 | 37,950,986 | 37,813,037 | 37,797,902 | 37,660,893 |
Cashflow
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $171.0K | $203.0K | $255.0K | $290.0K | $347.0K | $399.0K | $426.0K | $440.0K | $457.0K | $458.0K | $467.0K | $462.0K | $458.0K | $467.0K | $462.0K | $439.0K | |
| Stock-based Comp | $552.0K | $545.0K | $1M | $407.0K | $625.0K | $709.0K | $1M | $1M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | |
| Restructuring | · | · | $1M | $0 | $0 | · | $-222.0K | $0 | $4M | · | · | · | · | · | · | · | |
| Other Non-cash | · | $-2M | · | · | · | $-3M | · | · | · | $-9M | · | · | · | $-9M | · | · | |
| Operating Cash Flow | $-7M | $-8M | $-7M | $-10M | $-10M | $-13M | $-14M | $-14M | $-16M | $-17M | $-14M | $-17M | $-15M | $-23M | $-18M | $-13M | |
| CapEx | · | · | $0 | $72.0K | · | · | $0 | $41.0K | $0 | $0 | $6.0K | $165.0K | $32.0K | $3.0K | $184.0K | $735.0K | |
| Investing Cash Flow | $8M | $8M | $1M | $18M | $11M | $15M | $12M | $17M | $18M | $10M | $16M | $13M | $14M | $29M | $16M | $1M | |
| Stock Issued | $19.0K | $6.0K | $5.0K | $0 | $14.0K | $0 | $29.0K | $0 | · | · | $106.0K | $0 | · | · | $144.0K | $0 | |
| Net Stock Activity | · | $6.0K | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $19.0K | $6.0K | $5.0K | $0 | $14.0K | $0 | $29.0K | $0 | $79.0K | $0 | $106.0K | $0 | · | · | $144.0K | $0 | |
| Net Change in Cash | $1M | $-94.0K | $-6M | $8M | $1M | $1M | $-2M | $3M | $2M | $-7M | $2M | $-4M | $-1M | $6M | $-1M | $-12M | |
| Free Cash Flow | · | · | · | · | · | · | · | · | · | $-17M | · | · | · | $-23M | · | · |
Rentabilität
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -167480.0% | -29234.6% | · | -355.1% | -510.5% | -991.4% | · | -1441.1% | -1772.3% | -324.1% | · | -719.3% | -1383.9% | -1008.5% | · | · | |
| Net Margin | -154400.0% | -27861.5% | · | -329.4% | -474.6% | -903.4% | · | -1330.1% | -1662.3% | -205.0% | · | -643.1% | -1260.1% | -929.9% | · | · | |
| EBITDA Margin | -167480.0% | -28453.8% | · | -355.1% | -510.5% | -958.8% | · | -1441.1% | -1772.3% | -315.4% | · | -719.3% | -1383.9% | -982.9% | · | · | |
| ROA | -13.3% | -10.8% | · | -8.2% | -8.6% | -9.7% | · | -10.7% | -13.5% | -6.2% | · | -7.7% | -8.0% | -7.0% | · | · | |
| ROE | -30.0% | -21.7% | · | -13.7% | -13.7% | -14.6% | · | -15.2% | -18.6% | -8.3% | · | -10.3% | -10.3% | -8.8% | · | · |
Liquidität & Solvenz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.6 | 3.5 | · | 3.6 | 3.1 | 3.1 | · | 3.2 | 4.3 | 5.7 | · | 6.7 | 7.4 | 8.1 | · | · | |
| Quick Ratio | 2.2 | 3.1 | · | 3.2 | 2.8 | 2.9 | · | 3.0 | 4.1 | 5.5 | · | 6.4 | 7.1 | 7.8 | · | · |
Effizienz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | · |
Pro Aktie
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $6.56 | $10.32 | · | $16.72 | $20.24 | $1.22 | · | $1.88 | $2.24 | $2.73 | · | $3.38 | $3.75 | $4.17 | · | · | |
| Revenue / Share | $0.00 | $0.02 | · | $1.13 | $0.94 | $0.03 | · | $0.03 | $0.03 | $0.14 | · | $0.07 | $0.04 | $0.05 | · | · | |
| Cash Flow / Share | · | $-4.77 | · | · | · | $-0.35 | · | · | · | $-0.44 | · | · | · | $-0.62 | · | · | |
| Cash / Share | $6.68 | $6.04 | · | $9.25 | $5.00 | $0.22 | · | $0.24 | $0.16 | $0.11 | · | $0.24 | $0.35 | $0.39 | · | · | |
| EPS (TTM) | $-21.98 | $-21.87 | · | $-27.67 | $-31.88 | $-38.54 | · | $-19.80 | $-12.30 | $-1.66 | · | $-1.89 | $-2.04 | $-2.17 | · | $-2.56 |
Bewertung (TTM)
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $5M | $6M | · | $5M | $4M | $4M | · | $10M | $11M | $11M | · | $7M | $7M | $7M | · | $5M | |
| Net Income TTM | $-29M | $-30M | · | $-43M | $-51M | $-63M | · | $-65M | $-66M | $-63M | · | $-71M | $-77M | $-81M | · | $-95M | |
| Market Cap | $7M | $8M | · | $10M | $11M | $307M | · | $496M | $574M | $1.07B | · | $790M | $972M | $1.05B | · | · | |
| P/E | -0.2 | -0.2 | · | -0.2 | -0.2 | -0.2 | · | -0.7 | -1.2 | -16.9 | · | -11.0 | -12.5 | -12.8 | · | -11.6 | |
| P/S | 1.6 | 1.2 | · | 2.0 | 2.7 | 84.3 | · | 50.7 | 51.4 | 94.3 | · | 109.7 | 143.3 | 155.9 | · | · | |
| P/B | 0.6 | 0.4 | · | 0.3 | 0.3 | 6.6 | · | 6.9 | 6.7 | 10.2 | · | 6.2 | 6.8 | 6.7 | · | · | |
| P / Tangible Book | 0.6 | 0.4 | · | 0.3 | 0.3 | 6.6 | · | 6.9 | 6.7 | 10.2 | · | 6.2 | 6.8 | 6.7 | · | 5.9 | |
| P / Cash Flow | · | -1.0 | · | · | · | -22.9 | · | · | · | -63.7 | · | · | · | -44.9 | · | · | |
| Earnings Yield | -570.9% | -541.3% | · | -520.1% | -552.5% | -481.8% | · | -152.8% | -82.0% | -5.9% | · | -9.1% | -8.0% | -7.8% | · | -8.6% |
Aktuellster Zeitraum links · fehlende Werte werden als · angezeigt
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Umsatz | $8M | $8M | $8M | $6M | $1M |
| Betriebsgewinnmarge % | -469.3% | -949.9% | -967.5% | -1576.6% | -7364.1% |
| Nettoergebnis | $-33M | $-63M | $-69M | $-88M | $-99M |
| Verwässerte EPS | $-17.85 | $-33.06 | $-1.83 | $-2.36 | $-2.97 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Liquiditätsgrad | 3.6 | 3.2 | 5.2 | 7.5 | 8.9 |
| Quick Ratio | 3.3 | 3.0 | 5.0 | 7.3 | 8.7 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Freier Cashflow | $-40M | $-61M | $-70M | $-78M | $-59M |
Institutionelle Eigentümer (13F) 24 Einreicher · $2.4M gesamt · Stand 30. Juni 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
Inhaber
24
Gehaltener Wert
$2.4M
Neue Positionen
2
Geschlossene Positionen
3
Institutionelle Aktivität — Q2 2026 vs. Vorquartal
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 2 (-4 vs. Vorquartal) | 3 (+1 vs. Vorquartal) | 5 (-1 vs. Vorquartal) | 4 (+1 vs. Vorquartal) | -17K |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| Sofinnova Investments, Inc. | $530.226 | 137.721 | 22,41% | Aktien |
| RENAISSANCE TECHNOLOGIES LLC | $379.706 | 98.625 | 16,05% | Aktien |
| Vivo Capital, LLC | $278.794 | 72.414 | 11,78% | Aktien |
| CITADEL ADVISORS LLC | $219.077 | 56.903 | 9,26% | Aktien |
| T3 Companies, LLC | $146.300 | 38.000 | 6,18% | Aktien |
| Board of Trustees of The Leland Stanford Junior University | $138.511 | 35.977 | 5,85% | Aktien |
| Pfizer Inc | $133.832 | 31.305 | 5,66% | Aktien |
| Lynx1 Capital Management LP | $118.580 | 30.800 | 5,01% | Aktien |
| NANO CAP NEW MILLENNIUM GROWTH FUND L P | $105.875 | 27.500 | 4,48% | Aktien |
| GEODE CAPITAL MANAGEMENT, LLC | $73.622 | 19.119 | 3,11% | Aktien |
| Shay Capital LLC | $59.436 | 15.438 | 2,51% | Aktien |
| VANGUARD GROUP INC | $55.782 | 10.179 | 2,36% | Aktien |
| BlackRock, Inc. | $37.388 | 9.711 | 1,58% | Aktien |
| VANGUARD CAPITAL MANAGEMENT LLC | $27.181 | 7.060 | 1,15% | Aktien |
| Nan Fung Group Holdings Ltd | $19.250 | 5.000 | 0,81% | Aktien |
| MORGAN STANLEY | $12.108 | 3.145 | 0,51% | Aktien |
| VANGUARD FIDUCIARY TRUST CO | $11.916 | 3.095 | 0,50% | Aktien |
| NewEdge Advisors, LLC | $9.740 | 2.530 | 0,41% | Aktien |
| Tower Research Capital LLC (TRC) | $6.584 | 1.710 | 0,28% | Aktien |
| UBS Group AG | $982 | 255 | 0,04% | Aktien |
| SBI Securities Co., Ltd. | $501 | 130 | 0,02% | Aktien |
| JPMORGAN CHASE & CO | $165 | 42 | 0,01% | Aktien |
| CITIGROUP INC | $158 | 41 | 0,01% | Aktien |
| BARCLAYS PLC | $23 | 6 | 0,00% | Aktien |
Aktivisten & 5%+-Eigentümer 4 Beteiligungen
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| Nan Fung Group Holdings Limited, NF Investment Holdings Limited, Pivotal bioVenture Partners Fund I, L.P., Pivotal bioVenture Partners Fund I G.P., L.P., Pivotal bioVenture Partners Fund I U.G.P. Ltd., Pivotal Partners Ltd, Pivotal Life Sciences Holdings Limited, Nan Fung Life Sciences Holdings Limited, Permwell Management Limited, NFLS Beta Limited, NFLS Platform Holdings Limited ×4 Einreichungen | 26. Februar 2026 | 4,60% | Änderung | · | SEC |
| Novo Holdings A/S ×6 Einreichungen | 4. Januar 2023 | · | Erste Einreichung | · | SEC |
| Pivotal bioVenture Partners Fund I, L.P., Pivotal bioVenture Partners Fund I G.P., L.P., Pivotal bioVenture Partners Fund I U.G.P., Ltd. | 17. Februar 2021 | · | Erste Einreichung | Passive Anlage | SEC |
| Sofinnova Venture Partners X, L.P. (“SVP X”), Sofinnova Management X, L.L.C. (“SM X”), Dr. Michael F. Powell (“Powell”), Dr. James I. Healy (“Healy”), Dr. Maha Katabi (“Katabi”) | 16. Februar 2021 | · | Erste Einreichung | Passive Anlage | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Unternehmensinsider 18 Insider · 6 Führungskräfte · 13 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| William P. Quinn | President, CEO and CFO | 18. September 2026 S | 25.384 | 3 | 3 | $-54.705 |
| Randall C Schatzman | Chief Executive Officer | 4. März 2024 A | 1.500 | 0 | 0 | $0 |
| Grant Yonehiro | Chief Operating Officer | 18. September 2026 S | 17.269 | 0 | 3 | $-43.834 |
| Sarah Nemec | Senior VP, Finance and PAO | 18. September 2026 S | 17.082 | 3 | 3 | $-22.851 |
| Edith A. Perez | Chief Medical Officer | 4. März 2024 A | 37.042 | 0 | 0 | $0 |
| David Dornan | Chief Scientific Officer | 18. Februar 2022 A | · | 0 | 0 | $0 |
| Laura Berner | Direktor | 10. Juni 2026 A | · | 0 | 0 | $0 |
| Jakob Dupont | Direktor | 10. Juni 2026 A | · | 0 | 0 | $0 |
| Brian O'Callaghan | Direktor | 10. Juni 2026 A | · | 0 | 0 | $0 |
| Nicole Onetto | Direktor | 10. Juni 2026 A | · | 0 | 0 | $0 |
| Kathleen Laporte | Direktor | 10. Juni 2026 A | 1.200 | 0 | 0 | $0 |
| Frank D. Lee | Direktor | 12. Juni 2024 A | · | 0 | 0 | $0 |
| Mahendra Shah | Direktor | 12. Juni 2024 A | 1.448.286 | 0 | 0 | $0 |
| Dr. James I. Healy | Direktor | 12. Juni 2024 A | 2.754.437 | 0 | 0 | $0 |
| Edgar Engleman | Direktor | 30. November 2023 S | 251.522 | 0 | 0 | $0 |
| Richard A Miller MD | Direktor | 12. Juni 2023 A | · | 0 | 0 | $0 |
| Ashish Siri Ram Khanna | Direktor | 9. Februar 2021 P | 1.200 | 0 | 0 | $0 |
| Novo Holdings A/S | 10%-Eigentümer | 13. Juli 2022 S | 3.703.991 | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
ETF-Besitz Gehalten von 1 ETF
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
| Fonds | Gewicht | Anteile | Stand | Quelle |
|---|---|---|---|---|
| VXF · VANGUARD INDEX FUNDS | 0,00% | 7.060 SH | 19. August 2026 | Täglich |
BOLT Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
Bewertung · 10 Analysten
KAUF
Median-Ziel
$7.00
+102,9%
2 20,0%
Starker Kauf
5 50,0%
Kauf
3 30,0%
Halten
0 0,0%
Verkauf
0 0,0%
Starker Verkauf
12-Monats-Kursziel
3 Analysten · 2026-09-28Mittelwert-Ziel $29.00 +740,6%
← Unter allen Zielen
Aktueller Preis $3.45
Tief$5.00
Mittelwert$29.00
Hoch$75.00
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
FY-Basis, Kurse zum Schlusskurs am Ende des letzten Geschäftsjahres jedes Unternehmens.
| Ticker | Marktkapitalisierung | P/E | Umsatz Vj. | Nettomarge | ROE | Bruttogewinnmarge |
|---|---|---|---|---|---|---|
| BOLT | $11M | -0.3 | 0.07% | -433.7% | -102.2% | · |
| IMNN | $13M | -0.6 | · | · | -298.2% | · |
| BIAF | · | · | · | · | · | · |
| ACXP | $6M | -0.5 | · | · | -180.3% | · |
| SKYE | $25M | -0.5 | · | · | -175.6% | · |
| LNAI | $513M | -2.7 | · | · | -586.4% | · |
| CELZ | · | -0.8 | -45.5% | · | · | · |
| ALZN | $5M | -0.4 | · | · | -598.1% | · |
| XBIO | · | -1.4 | 19.0% | · | · | · |
Neueste Nachrichten Aktuelle Schlagzeilen über dieses Unternehmen
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das + neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Quelle: SEC 10-Q eingereicht Aug 11, 2026